Effects of a lipid-based nutrient supplement during pregnancy and lactation on maternal plasma fatty acid status and lipid profile: Results of two randomized controlled trials.

What Was Tested

Researchers studied Copper (Supplement) in this randomized controlled trial publication.

It is unknown whether a novel small-quantity lipid-based nutrient supplement (SQ-LNS) containing alpha-linolenic (ALA) and linoleic acids impacts maternal plasma lipids and fatty acid status.

The researchers measured plasma fatty acids (wt%) and lipid concentrations at 36 wk gestation and breast milk fatty acids (wt%) at 6 months postpartum in a subsample of women enrolled in a randomized controlled trial studying the effects of SQ-LNS on birth outcomes and child growth.

Who Took Part

By PubMed's age tags, the people studied were young adults and adults, women only.

How the Study Was Run

In design terms this was a randomized study.

Random assignment meant chance, not the researchers, decided who got Copper (Supplement) and who got the comparison, which limits bias.

What Was Measured

The researchers measured plasma fatty acids (wt%) and lipid concentrations at 36 wk gestation and breast milk fatty acids (wt%) at 6 months postpartum in a subsample of women enrolled in a randomized controlled trial studying the effects of SQ-LNS on birth outcomes and child growth.

At 36 wk, plasma ALA levels were higher in those receiving SQ-LNS.

PubMed files the paper under topics including Dietary Supplements, Fatty Acids, Folic Acid, Gestational Age, Ghana, Lactation and Linoleic Acid.

The authors tagged it with the keywords Cholesterol, Lipids, Omega-3 fatty acids, Pregnancy and Supplementation.

What This Means in Plain Language

The paper is a randomized study of Copper (Supplement).

The publication is from 2017 (Prostaglandins, leukotrienes, and essential fatty acids), a journal based in Scotland.

More context: the Copper (Supplement) compound page, all human trials.